Literature DB >> 27326165

An update on coronary bypass graft intervention.

Debabrata Dash.   

Abstract

Coronary artery bypass grafting (CABG) remains one of the most common surgical procedures. In spite of great advancements like arterial grafts and off-pump bypass procedure, recurrent ischaemia may ensue with the lesions of the graft. Early postoperative ischaemia (<30 days) is due to graft occlusion or stenosis, and percutaneous coronary intervention (PCI) is frequently feasible. Late postoperative ischaemia (>3 years) is most often due to a saphenous vein graft (SVG) lesion. Multiple diseased grafts, reduced left ventricular function, and available arterial conduits favour repeat CABG, whereas, a patent left internal mammary artery to left anterior descending favours PCI. Embolic protection reduces atheroembolic myocardial infarction during PCI of SVG and should be routinely used in treatment of SVG lesions. A variety of vasodilators may reduce the risk of or mitigate the consequences of no-reflow. Drug-eluting stents reduce restenosis in SVG grafts, and have become the default strategy for many interventionalists.

Entities:  

Keywords:  Coronary Artery Disease

Year:  2014        PMID: 27326165      PMCID: PMC4832711          DOI: 10.1136/heartasia-2013-010478

Source DB:  PubMed          Journal:  Heart Asia        ISSN: 1759-1104


  37 in total

1.  Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.

Authors:  Marco Roffi; Debabrata Mukherjee; Derek P Chew; Deepak L Bhatt; Leslie Cho; Mark A Robbins; Khaled M Ziada; Danielle M Brennan; Stephen G Ellis; Eric J Topol
Journal:  Circulation       Date:  2002-12-10       Impact factor: 29.690

2.  Preliminary results of the INSPIRE trial with the novel MGuard stent system containing a protection net to prevent distal embolization.

Authors:  Felipe Maia; J Ribamar Costa; Alexandre Abizaid; Fausto Feres; Ricardo Costa; Rodolfo Staico; Dimytri Siqueira; Vinicius Esteves; Amanda Sousa; J Eduardo Sousa
Journal:  Catheter Cardiovasc Interv       Date:  2010-07-01       Impact factor: 2.692

3.  Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques.

Authors:  Rasha Al-Lamee; Alfonso Ielasi; Azeem Latib; Cosmo Godino; Massimo Ferraro; Francesco Arioli; Marco Mussardo; Daniela Piraino; Filippo Figini; Mauro Carlino; Matteo Montorfano; Alaide Chieffo; Antonio Colombo
Journal:  Am J Cardiol       Date:  2010-10-26       Impact factor: 2.778

4.  Beyond embolic protection for saphenous vein graft disease.

Authors:  Lowell F Satler
Journal:  Catheter Cardiovasc Interv       Date:  2008-11-01       Impact factor: 2.692

5.  Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.

Authors:  Paul Vermeersch; Pierfrancesco Agostoni; Stefan Verheye; Paul Van den Heuvel; Carl Convens; Nico Bruining; Frank Van den Branden; Glenn Van Langenhove
Journal:  J Am Coll Cardiol       Date:  2006-11-28       Impact factor: 24.094

6.  Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience.

Authors:  W B Hillegass; N A Dean; L Liao; R G Rhinehart; P R Myers
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

7.  Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon.

Authors:  S Sdringola; A Assali; M Ghani; A Yepes; O Rosales; G W Schroth; K Fujise; H V Anderson; R W Smalling
Journal:  Catheter Cardiovasc Interv       Date:  2000-12       Impact factor: 2.692

8.  Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators.

Authors:  M P Savage; J S Douglas; D L Fischman; C J Pepine; S B King; J A Werner; S R Bailey; P A Overlie; S H Fenton; J A Brinker; M B Leon; S Goldberg
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

9.  Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients.

Authors:  Alanna Coolong; Donald S Baim; Richard E Kuntz; A James O'Malley; Sachin Marulkar; Donald E Cutlip; Jeffrey J Popma; Laura Mauri
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

10.  Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft.

Authors:  Laurent Leborgne; Edouard Cheneau; Augusto Pichard; Andrew Ajani; Rajbabu Pakala; Hamid Yazdi; Lowell Satler; Kenneth Kent; William O Suddath; Ellen Pinnow; Daniel Canos; Ron Waksman
Journal:  Am Heart J       Date:  2003-09       Impact factor: 4.749

View more
  2 in total

1.  Procedural Results and Immediate Outcomes following De Novo Saphenous Venous Graft Interventions.

Authors:  Lalita Nemani; Maddury Jyotsna; Malleswara Rao D
Journal:  Int J Angiol       Date:  2018-03-26

2.  Association of CHA2DS2-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI.

Authors:  Orhan Maden; Özge Çakmak Karaaslan; Yücel Kanal; İdris Yakut; Nezaket Merve Yaman; Hasan Can Könte; Kevser Gülcihan Balcı; Mehmet Timur Selçuk; Hatice Selçuk
Journal:  Herz       Date:  2021-10-04       Impact factor: 1.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.